ArticleBMC cancer2026
Efficacy and safety of nab-paclitaxel plus PD-1 inhibitor in elderly patients with advanced squamous lung cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the clinical efficacy and safety of nab-paclitaxel in combination with PD-1 inhibitors in elderly patients with advanced squamous cell lung cancer.
methodsA retrospective analysis was performed on 40 elderly patients with advanced squamous cell lung cancer treated at the affiliated Zhangjiagang Hospital of Soochow University between March 2020 and July 2024. Patients were assigned to either the chemotherapy group (n = 18), receiving nab-paclitaxel monotherapy, or the combination therapy group (n = 22), receiving nab-paclitaxel plus a PD-1 inhibitor. Treatments were administered every three weeks (per cycle). Short-term efficacy and adverse events were evaluated after every 2–3 cycles, and patients were followed up to assess the incidence of adverse reactions and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
resultsCompared with the chemotherapy group, patients in the combination therapy group demonstrated improved clinical outcomes, including higher objective response rate(31.8% vs. 22.2%) and disease control rates (86.4% vs. 66.7%), as well as a longer median overall survival time (19 vs. 9 months). In addition, the combination therapy group exhibited significantly higher 6-month (100% vs. 77.8%) and 1-year (72.2% vs. 35.3%) survival rates. The most frequently observed adverse events were leukopenia, anemia, fatigue, nausea and vomiting, myalgia, cough, and interstitial pneumonia, all of which were generally manageable.
conclusionNab-paclitaxel combined with PD-1 inhibitors demonstrated superior short-term efficacy and an acceptable safety profile compared with chemotherapy alone in elderly patients with advanced squamous cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.